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Clinician’s Corner
Eight-year-old girl with hepatomegaly
CASE DESCRIPTION
An 8-year-old girl was referred for abdominal pain and elevated liver transam-
inases. She was previously healthy and was not on any medications. There was 
no prior history of blood transfusions, toxin exposures or parenteral nutrition. 
Her parents were nonconsanguineous, and of French and Irish descent. Her 
family has no history of liver diseases but maternal and paternal grandparents 
have elevated cholesterol.
Her weight was 25.5 kg (27th percentile), height 127 cm (21st percentile) 
and body mass index (BMI) was 15.8 kg/m2 (42nd percentile). On abdominal 
examination, both liver and spleen were enlarged. There was no scleral icterus 
or abnormal skin findings or xanthomatosis.
Her liver enzymes revealed elevated transaminases. Total bilirubin was high 
at 32.7 (<17) µmol/L and direct bilirubin was 5 µmol/L. There was no coagu-
lopathy. Abdominal ultrasound demonstrated her liver to be at near the 95th 
percentile while her spleen was also enlarged. Doppler study of liver vasculature 
was normal with no evidence of portal hypertension. Laboratory investigations 
are outlined in Table 1. Given the hepatomegaly, a lipid profile was performed, 
demonstrating elevated cholesterol of 6.11 (≤5.20) mmol/L and low HDL cho-
lesterol of 0.83 (≥1.30) mmol/L. Further studies led to the diagnosis.
CASE DIAGNOSIS: LYSOSOMAL ACID LIPASE (LAL) 
DEFICIENCY (CHOLESTERYL ESTER STORAGE DISEASE)
Studies for infectious and autoimmune hepatitis, α-1 antitrypsin, Wilson’s 
disease and celiac disease were negative. She had elevated cholesterol at 
6.11 mmol/L and low HDL cholesterol at 0.83 mmol/L. Liver biopsy revealed 
severe diffuse, microvesicular steatosis with bridging fibrosis (Batts–Ludwig 
stage ¾) and abundant foamy macrophages (Figure 1A and 1B).
Further metabolic testing showed low activity of LAL of 13 (80–230) 
pmol/h/dried blood dot punch. Plasma chitotriosidase activity was also 
elevated at 545 (6–121) nmol/h/mL, which is a marker enzyme for various 
lysosomal storage disorders. She was diagnosed with lysosomal acid lipase defi-
ciency (LALD), also known as cholesteryl ester storage disease. Genetic testing 
confirmed this diagnosis, showing two pathogenic mutations in the lysosomal 
acid lipase gene (LIPA) (c.684delT and c.894G>A). A  low fat diet was initi-
ated to address her dyslipidemia. Lipid-lowering agents such as statins were not 
initiated as evidence for efficacy was poor. The use of enzyme therapy, specifi-
cally sebelipase alfa is available for adults in USA but it is currently waiting for 
approval in Canada.
LALD is an autosomal recessive, metabolic condition characterized by muta-
tions in the LIPA. Deficient LAL activity leads to accumulation of cholesteryl 
esters in the liver, spleen, lymph nodes, thymus, adrenal gland and small bowel. 
This condition can present early as the infantile form called Wolman disease 
(WD) or later in life as LALD affecting children and adults. It occurs with an 
incidence of 1/300,000 to 1/500,000 in the Caucasian population, with the 
highest incidence in the German population of 1/40,000 (1).
Infants with WD present around 2 to 4 months of age with massive hepato-
splenomegaly, feeding difficulties and failure to thrive. These findings in combi-
nation with adrenal calcification are pathognomonic for WD. The presentation 
in patients with late-onset LALD can be subtle and thus, unrecognized. Almost 
all individuals will have hepatomegaly with or without splenomegaly. Other 
nonspecific gastrointestinal symptoms include vomiting, diarrhea, failure to 
thrive and abdominal pain. Eighty to ninety per cent of individuals have elevated 
transaminases, low HDL cholesterol, high total cholesterol and triglycerides. 
Hepatic steatosis may be seen on ultrasound. Liver biopsy shows microvesic-
ular steatosis from lysosomal accumulation of CE and triglycerides plus foamy 
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Table 1. Investigations summary
Investigation Result Range
Aspartate aminotransferase (U/L) 117 ≤33
Alanine aminotransferase (U/L) 86 ≤32
Alkaline phosphatase (U/L) 308 ≤300
Gamma-glutamyltranspeptidase (U/L) 28 ≤31
International normalized ratio 1.2 0.9–1.1
Total bilirubin (µmol/L) 32.7 3.4–17.1
Direct bilirubin (µmol/L) 5 ≤5
Partial thromboplastin time (s) 28 23–32
Albumin (g/L) 45 38–54
Hemoglobin (g/L) 132 110–160
Platelets (×109/L) 320 150–400
White blood count (×109/L) 4.8 5–12
Cholesterol (mmol/L) 6.11 ≤5.20
Triglycerides (mmol/L) 1.26 ≤1.70
HDL cholesterol (mmol/L) 0.83 ≥1.30
LDL cholesterol (calc) (mmol/L) 4.71 —
Non-HDL cholesterol (mmol/L) 5.28 —
Cholesterol: HDL ratio 7.4 —
Ferritin (µg/L) 51.9 13–150
Alpha-fetoprotein (µg/L) 2.4 ≤5
Acylcarnitine (profile, total and free) Normal —
Urine organic acids Negative —
Plasma amino acids Negative —
Investigations were completed to rule out other causes of hepatomegaly. Abnormal 
values are bolded.
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macrophages with lipid and ceroid. This condition can progress to liver fibrosis 
and micronodular cirrhosis. Diagnosis is based on finding reduced LAL level 
in peripheral blood leukocytes. Reduced LAL activity in affected individuals 
ranges from 1% to 12% of normal, with residual enzymatic activity correlating 
with disease onset and rate of disease progression (2). Gene sequencing of the 
LIPA is also available.
The differential diagnosis for hepatomegaly includes inflammation (infec-
tions, toxins, autoimmune diseases), inappropriate storage of different materi-
als like lipids or glycogen, primary or metastatic liver malignancies and hepatic 
vascular congestion (veno-occlusive disease, heart failure, hepatic vein throm-
bosis). Clinicians should suspect this condition if a patient presents with raised 
transaminases and an abnormal lipid profile, especially in a non-obese child. 
Early recognition is essential to halt progression to cirrhosis, which has been 
seen in patients as young as 5 years of age. Those with hepatic fibrosis can 
have complications such as portal hypertension, ascites and esophageal vari-
ces. Treatment with statins has not been effective in improving liver disease. 
Those with liver failure may require transplantation. A recombinant human 
LAL, sebelipase alfa, has demonstrated improvements in transaminases and 
lipid profile. Children with LALD should be monitored for hepatic fibrosis. 
Evaluation should include annual liver enzymes and function tests, lipid panel 
and chitotriosidase (a macrophage inflammatory marker found to be elevated in 
LALD). Liver and spleen imaging should occur periodically along with cardio-
vascular assessment. Genetic counselling should be considered for parents of 
the affected child for future pregnancies.
CLINICAL PEARLS
• Paediatricians encountering patients with hepatomegaly should consider a 
broad differential diagnosis. In children with fatty liver disease, consider-
ation should be given to screening for metabolic diseases like LALD, mito-
chondrial hepatopathy and Wilsons, especially if their BMI is normal.
• Due to the nonspecific presentation of LALD, suspicion for this diagnosis 
should be high, especially in the context of hepatosplenomegaly, elevated 
transaminases and abnormal lipid profile.
• Early recognition of this under-recognized condition will facilitate man-
agement by specific enzyme replacement therapy to halt progression of the 
disease.
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Figure 1. Liver biopsy. (A) Liver biopsy showing diffuse micro vesicular steatosis. (B) Bridging fibrosis seen with Masson trichrome stain (blue).
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